Prognosis in relation to blood pressure variability: con side of the argument.
From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).
Kei
K
Asayama
From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).
Fang-Fei
FF
Wei
From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).
Azusa
A
Hara
From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).
Tine W
TW
Hansen
From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).
Yan
Y
Li
From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.). jan.staessen@med.kuleuven.be.
Jan A
JA
Staessen
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D001795:Blood Pressure Determination / Q000379:methods; D018660:Blood Pressure Monitoring, Ambulatory / Q000379:methods; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D011379:Prognosis; D018570:Risk Assessment; D012737:Sex Factors
D000959:Antihypertensive Agents